AbbVie Inc (ABBV)

65.64
0.01 0.02
NYSE : Health Care
Prev Close 65.65
Open 65.51
Day Low/High 65.32 / 66.11
52 Wk Low/High 55.06 / 68.12
Volume 4.01M
Avg Volume 7.09M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 104.41B
EPS 3.70
P/E Ratio 13.59
Div & Yield 2.56 (3.90%)

Latest News

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- Priority review granted in Japan, following EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively

AbbVie, Abbott Laboratories, Amplify Snacks, Skyworks Solutions: 'Mad Money' Lightning Round

AbbVie, Abbott Laboratories, Amplify Snacks, Skyworks Solutions: 'Mad Money' Lightning Round

Jim Cramer is bullish on AbbVie and Abbott Laboratories, but he's bearish on Sonic and Ionis Pharmaceuticals.

This Bull Could Feel the Chill: Cramer's 'Mad Money' Monday Recap

This Bull Could Feel the Chill: Cramer's 'Mad Money' Monday Recap

Cramer still thinks we need a rate hike, but he's ready for a backlash in some sectors -- and you should be, too.

The New #167 Most Shorted S&P 500 Component: AbbVie

The New #167 Most Shorted S&P 500 Component: AbbVie

The most recent short interest data has been released for the 02/28/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

AbbVie Is a Screaming Dividend Growth Buy... Here's Why

AbbVie Is a Screaming Dividend Growth Buy... Here's Why

AbbVie is unloved by the market, but the stock is poised to generate double-digit returns for shareholders. In addition, AbbVie currently has a high yield of 4.0%.

How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More

How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

AbbVie, a 2017 Dividend Pick, Could Turn to the Upside

AbbVie, a 2017 Dividend Pick, Could Turn to the Upside

After months of sideways action, shares of ABBV are on the cusp of an upside breakout.

AbbVie Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

AbbVie Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis*

Bulls Are Shorn of Their Horns

Let's explore the possible reasons for the change.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

AbbVie Becomes #173 Most Shorted S&P 500 Component, Replacing Newell Brands

AbbVie Becomes #173 Most Shorted S&P 500 Component, Replacing Newell Brands

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Portfolio Update: AbbVie, Pfizer and Sonoco Report Earnings; and Don't Miss These Must-Own Dates!

An update of earnings, payout dates and upcoming dividend reminders.

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

You Can Also Get High on Marijuana Stocks -- Here's How

You Can Also Get High on Marijuana Stocks -- Here's How

Everyone else is doing it.

Abbvie Shares Fall on Mixed Earnings Report

Abbvie Shares Fall on Mixed Earnings Report

The biotech saw shares fall 2.3% after reporting in-line earnings and worse-than-expected revenue.

Create a 'Barbell' of Value, Income Stocks

Create a 'Barbell' of Value, Income Stocks

Value stocks will extend their outperformance over growth stocks that began last year.

Market Recon: Danger Is Coming to a Market Near You

Market Recon: Danger Is Coming to a Market Near You

What do you do when the music stops? Are you the kid without a chair?